Patient Engagement Investigation of NMS Assist

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorNewcastle University

About this trial

Parkinson's can cause a wide range of non-motor symptoms (NMS), including pain and problems with mental health, memory and sleep. These affect the quality of life of people with Parkinson's (PwP) and their care partners (CP). If these issues are not recognised and managed quickly, they can result in escalating problems. Many PwP are unsure of the extent and variety of the NMS and how simple adjustments at home could improve them. We have developed a digital system to help PwP monitor their non-motor symptoms and develop skills to self-manage them.

Such a tool needs to be simple to use, safe and effective. We will ask 30 PwP and CPs to use the digital tool for 6 months, and we will monitor how they use the tool. PwP and CPs will be asked if they feel more knowledgeable and confident to manage their own symptoms whilst being better able to discuss a problem with their healthcare professional.

A smaller group of participants will discuss their experiences in more detail to help pinpoint aspects that work well and those needing adjustment and development.

It is thought that the use of this system will result in improved quality of life and increased knowledge and confidence for managing symptoms while safely reducing the time spent by healthcare professionals on manageable non-motor symptoms.

Eligibility criteria

Qualifiers

Age 18 years or over

Have compatible smartphone/data access (access to a digital device is a necessary prerequisite of system use, and the formative usability study had success in recruiting participants with varying levels of experience with smartphones)

Be fluent in English

Able and willing to provide informed consent

Disqualifiers

Previous involvement in the development or testing of the digital system

In a dependent/unequal relationship with the research or care teams or any PPI representatives

Secondary cause of Parkinsonism

Significant cognitive impairment or a diagnosis of Parkinson's disease dementia

Trial design

Treatments tested in this trial

  • NMS Assist

Treatment groups

30 Participants
are divided into 1 treatment group

Sponsors and collaborators